Trial Profile

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2023 Pre-specified interim Results (n=78) presented at the 65th American Society of Hematology Annual Meeting and Exposition
01 Feb 2023 Results of pre-specified futility analysis assessing the early clinical benefit and tolerability of Ruxolitinib in previously untreated PV patients , published in the Annals of Hematology
13 Dec 2022 Interim results (n=95) of pre-specified analysis reporting efficacy and safety data of ET patients presented at the 64th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com